Therapeutic Approach

Archive: October, 2017

Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES (October 31, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with an initial focus on developing the first FDA approved treatment for lactose intolerance, today reported financial results and a business update for […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with an initial focus on developing the first FDA approved treatment for lactose intolerance, today announced the pricing of […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance

Los Angeles, California, October 3, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering with total gross proceeds to the Company of approximately $23 […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD